Triomics nabs $22M to bring oncology-specific AI to cancer centers
Triomics has secured $22 million in Series B funding to enhance its AI platform for oncology. The startup aims to streamline administrative tasks for oncologists, improving efficiency and patient care. With a fourfold increase in its customer base over the past year, Triomics is rapidly expanding in a competitive market.
- ▪Triomics raised $22 million in Series B funding led by Battery Ventures.
- ▪The platform helps oncologists automate data-heavy tasks like clinical trial matching.
- ▪Triomics has expanded its enterprise customer base fourfold in the past year.
Opening excerpt (first ~120 words) tap to expand
Triomics, a startup building an AI-powered platform to help oncologists and administrative staff automate data-heavy tasks like clinical trial matching and appointment prep, has raised $22 million in Series B funding. The round was led by Battery Ventures, with participation from returning backers Nexus Venture Partners, Lightspeed, Y Combinator, and others. The good news is that oncology breakthroughs are keeping patients alive longer. That welcome trend, however, is creating dense, multi-year medical records that take healthcare staff a long time to review and decipher. A typical medical chart includes physician progress notes, imaging and pathology reports, and even scans of faxes.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at TechCrunch.
Discussion
0 commentsMore from TechCrunch
